BME100 f2013:W1200 Group9 L1

From OpenWetWare
Jump to navigationJump to search
BME 100 Fall 2013 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help


OUR TEAM

Name: Kenna Lum
Role(s)
Name: Jessica Stradford
Role(s)
Name: Salvador Avina
Role(s)
Name: Michelle Sigona
Role(s)
Name: Rachael Hall
Role(s)

LAB 1 WRITE-UP

Independent and Dependent Variables

Independent Variable: The different doses of the lipopolysaccharide given to the patients
Dependent Variable: The amount of Inflammotin it creates



Experimental Design

We will experiment with ten groups of people, five groups of women and five groups of men.

There will be ten people in each of the ten groups, one hundred total patients.


For our experiment, we will take each group and give them varying doses of the lipopolysaccharide. Two groups (one of men and one of women) will have the same dose. Two groups will get a dose of 10mg, two will get 8mg, two will get 6mg, two will get 4mg, and two will get 2mg. Will will give the doses in the morning and then take blood samples using ELISA in the early afternoon. Based on those results, we will be able to conclude the smallest amount of the drug lipopolysaccharide that will increase inflammotin. If no increases are measured, we will distribute another dose of lipopolysaccharide and begin the process again.




Subject Selection

The minimum age required will be 65 years. Groups of both men and women, race, geographic location, lifestyle, and financial status will be randomized.





Sources of Error and Bias

Some of the errors in the experiment will include other drugs that the patients are taking, incorrect amount of the dosage of the drug, and previous blood conditions and health problems.
Some potential biases to take into account include patients with higher social standing versus lower social standings, race, age groups, and gender. An option to avoid these potential bias is conducting a double blind trial on patients.